TG Therapeutics Inc
NASDAQ:TGTX
TG Therapeutics Inc
TG Therapeutics Inc. stands at the intersection of innovation and ambition in the biopharmaceutical industry, with its eyes set firmly on revolutionizing the treatment of B-cell diseases. Founded by Michael S. Weiss, a proven leader in the biopharma sector, this company has carved a niche by focusing on the development and commercialization of novel therapies for cancer and autoimmune diseases. Central to its strategy is harnessing the science behind B-cells, which play a crucial role in the immune system and are often implicated in malignancies such as lymphoma and leukemia. TG Therapeutics builds its business model around creating value through its clinical development pipeline, championed by therapies like ublituximab and umbralisib. These treatments, which target different pathways within B-cells, illustrate the company’s commitment to advancing precision medicine.
Revenue generation for TG Therapeutics hinges on successfully bringing its innovative therapies to market. The company follows a path similar to many in the biotech sphere: investing significantly in research and development to shepherd promising drug candidates through clinical trials. Once a therapy gains regulatory approval, TG Therapeutics moves into the commercialization phase, seeking to monetize its investments through sales. The company's ability to navigate regulatory pathways, establish strategic partnerships, and optimize its commercial efforts is crucial to converting its scientific prowess into financial returns. As a public company, it also utilizes equity financing to fund its expansive R&D endeavors, ensuring that it remains at the forefront of tackling some of the most challenging and prevalent diseases today.
TG Therapeutics Inc. stands at the intersection of innovation and ambition in the biopharmaceutical industry, with its eyes set firmly on revolutionizing the treatment of B-cell diseases. Founded by Michael S. Weiss, a proven leader in the biopharma sector, this company has carved a niche by focusing on the development and commercialization of novel therapies for cancer and autoimmune diseases. Central to its strategy is harnessing the science behind B-cells, which play a crucial role in the immune system and are often implicated in malignancies such as lymphoma and leukemia. TG Therapeutics builds its business model around creating value through its clinical development pipeline, championed by therapies like ublituximab and umbralisib. These treatments, which target different pathways within B-cells, illustrate the company’s commitment to advancing precision medicine.
Revenue generation for TG Therapeutics hinges on successfully bringing its innovative therapies to market. The company follows a path similar to many in the biotech sphere: investing significantly in research and development to shepherd promising drug candidates through clinical trials. Once a therapy gains regulatory approval, TG Therapeutics moves into the commercialization phase, seeking to monetize its investments through sales. The company's ability to navigate regulatory pathways, establish strategic partnerships, and optimize its commercial efforts is crucial to converting its scientific prowess into financial returns. As a public company, it also utilizes equity financing to fund its expansive R&D endeavors, ensuring that it remains at the forefront of tackling some of the most challenging and prevalent diseases today.
Record Revenue: TG Therapeutics reported approximately $616 million in global revenue for 2025, driven by $594 million U.S. BRIUMVI net sales, with Q4 U.S. sales of $183 million, representing 92% year-over-year and 20% sequential growth.
Strong Profitability: Operating income reached $123 million for the year, and net income was $447.2 million, including a $340 million nonrecurring tax benefit.
Guidance Reaffirmed: The company reaffirmed 2026 U.S. BRIUMVI net revenue guidance of $825 million to $850 million and total global revenue of $875 million to $900 million.
Cash Flow & Buybacks: TG expects to maintain positive cash flow in 2026 and completed a $100 million share repurchase, with another $100 million authorized.
Pipeline Momentum: Key catalysts ahead include results from the ENHANCE trial (simplified BRIUMVI dosing), progress on the subcutaneous BRIUMVI program, and initial data from additional autoimmune indications.
Commercial Execution: Record new patient starts, expanding prescriber base, and strong persistence are driving growth. Direct-to-consumer initiatives and field force expansion are supporting further gains.
